Snowdome Annual Review for 2020

We are incredibly proud to share with you our 2020 Annual Review featuring financial highlights from 2019-2020. It was a year full of challenges, one that sharpened our focus on what is truly important and dear to us. We believe in our mission to accelerate next-generation treatments for Australian blood cancer patients to help them … Continued

Clinical trials bring hope

For many patients access to a clinical trial can literally save their life.  In speaking to The West Australian newspaper, Prof Chan Cheah told reporter Katie Hampson, when he trained in Melbourne and the U.S he had a range of trials he could put a patient on when they had exhausted all other options.  These options … Continued

Understanding clinical trials

Clinical trials are often the gateway to new treatments for patients with blood cancer. When new therapies are being tested they go through various stages. If you have ever wondered about the various clinical trial stages and what they mean, below is a synopsis to provide you with some insight. Phase I trials are the … Continued

Five new treatments approved for blood cancer by the FDA

In the last six weeks the U.S. Food and Drug Administration (FDA) has approved five additional treatments for blood cancer.  The rate at which new treatments are being approved in the U.S. is incredibly encouraging.  It demonstrates the progress researchers are making in finding new and novel ways to treat cancer.  It is also frustrating … Continued

Partnering to provide more hope to blood cancer patients

Prof Miles Prince AM was devastated when back in 2018, his patient Tom Long had to embark on a journey to Seattle USA in order to receive chimeric antigen receptor T-cell (CAR T) therapy via a clinical trial.  He knew that while Australia had the clinical expertise to administer CAR T-cell therapy, we did not … Continued

New multiple myeloma treatment approved in the U.S.

In June 2019, the U.S. FDA approved selinexor (Xpovio) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.  Myeloma patients had to have been treated with at least four prior therapies.  In November 2020, the results of the BOSTON study were published which demonstrated the benefits of using selinexor earlier in … Continued

Latest grants announced in Australia-US blood cancer research co-funding partnership

Two new research projects co-funded through a partnership between America’s The Leukemia & Lymphoma Society (LLS), Snowdome Foundation and Leukaemia Foundation will focus on acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS), seeking to improve understanding and treatment of these blood cancers. Prof. Ravindra Majeti, Stanford University in the US, will join with Assoc. Prof. … Continued

Professor John Pimanda – Expediting drug discovery in MDS

Professor Pimanda is incredibly curious. His observations around why cells behave in certain ways and respond variably to stimuli led him down a cell biology research path.  He was particularly drawn to blood stem cell development and maturation and the disruption of this orderly process in blood cancers. In 2008, when John was setting up … Continued